168 related articles for article (PubMed ID: 28818232)
1. Review of the endothelial pathogenic mechanism of TIE2-related venous malformation.
Du Z; Zheng J; Zhang Z; Wang Y
J Vasc Surg Venous Lymphat Disord; 2017 Sep; 5(5):740-748. PubMed ID: 28818232
[TBL] [Abstract][Full Text] [Related]
2. Functional analysis of a mutant form of the receptor tyrosine kinase Tie2 causing venous malformations.
Morris PN; Dunmore BJ; Tadros A; Marchuk DA; Darland DC; D'Amore PA; Brindle NP
J Mol Med (Berl); 2005 Jan; 83(1):58-63. PubMed ID: 15526080
[TBL] [Abstract][Full Text] [Related]
3. Tie2-R849W mutant in venous malformations chronically activates a functional STAT1 to modulate gene expression.
Hu HT; Huang YH; Chang YA; Lee CK; Jiang MJ; Wu LW
J Invest Dermatol; 2008 Sep; 128(9):2325-33. PubMed ID: 18401423
[TBL] [Abstract][Full Text] [Related]
4. Mutant Tie2 causing venous malformation signals through Shc.
Morris PN; Dunmore BJ; Brindle NP
Biochem Biophys Res Commun; 2006 Jul; 346(1):335-8. PubMed ID: 16756945
[TBL] [Abstract][Full Text] [Related]
5. Venous malformation-causative TIE2 mutations mediate an AKT-dependent decrease in PDGFB.
Uebelhoer M; Nätynki M; Kangas J; Mendola A; Nguyen HL; Soblet J; Godfraind C; Boon LM; Eklund L; Limaye N; Vikkula M
Hum Mol Genet; 2013 Sep; 22(17):3438-48. PubMed ID: 23633549
[TBL] [Abstract][Full Text] [Related]
6. AKT/FOXO1 axis links cross-talking of endothelial cell and pericyte in TIE2-mutated venous malformations.
Si Y; Huang J; Li X; Fu Y; Xu R; Du Y; Cheng J; Jiang H
Cell Commun Signal; 2020 Aug; 18(1):139. PubMed ID: 32867785
[TBL] [Abstract][Full Text] [Related]
7. Transgenic Expression of A Venous Malformation Related Mutation,
Du Z; Ma HL; Zhang ZY; Zheng JW; Wang YA
Int J Med Sci; 2018; 15(4):385-394. PubMed ID: 29511374
[TBL] [Abstract][Full Text] [Related]
8. Rapamycin improves TIE2-mutated venous malformation in murine model and human subjects.
Boscolo E; Limaye N; Huang L; Kang KT; Soblet J; Uebelhoer M; Mendola A; Natynki M; Seront E; Dupont S; Hammer J; Legrand C; Brugnara C; Eklund L; Vikkula M; Bischoff J; Boon LM
J Clin Invest; 2015 Sep; 125(9):3491-504. PubMed ID: 26258417
[TBL] [Abstract][Full Text] [Related]
9. Somatic mutations in angiopoietin receptor gene TEK cause solitary and multiple sporadic venous malformations.
Limaye N; Wouters V; Uebelhoer M; Tuominen M; Wirkkala R; Mulliken JB; Eklund L; Boon LM; Vikkula M
Nat Genet; 2009 Jan; 41(1):118-24. PubMed ID: 19079259
[TBL] [Abstract][Full Text] [Related]
10. Common and specific effects of TIE2 mutations causing venous malformations.
Nätynki M; Kangas J; Miinalainen I; Sormunen R; Pietilä R; Soblet J; Boon LM; Vikkula M; Limaye N; Eklund L
Hum Mol Genet; 2015 Nov; 24(22):6374-89. PubMed ID: 26319232
[TBL] [Abstract][Full Text] [Related]
11. STAT1 activation by venous malformations mutant Tie2-R849W antagonizes VEGF-A-mediated angiogenic response partly via reduced bFGF production.
Huang YH; Wu MP; Pan SC; Su WC; Chen YW; Wu LW
Angiogenesis; 2013 Jan; 16(1):207-22. PubMed ID: 23086340
[TBL] [Abstract][Full Text] [Related]
12. Ponatinib Combined With Rapamycin Causes Regression of Murine Venous Malformation.
Li X; Cai Y; Goines J; Pastura P; Brichta L; Lane A; Le Cras TD; Boscolo E
Arterioscler Thromb Vasc Biol; 2019 Mar; 39(3):496-512. PubMed ID: 30626204
[TBL] [Abstract][Full Text] [Related]
13. Constitutive Active Mutant TIE2 Induces Enlarged Vascular Lumen Formation with Loss of Apico-basal Polarity and Pericyte Recruitment.
Cai Y; Schrenk S; Goines J; Davis GE; Boscolo E
Sci Rep; 2019 Aug; 9(1):12352. PubMed ID: 31451744
[TBL] [Abstract][Full Text] [Related]
14. A Tie2 kinase mutation causing venous malformations increases phosphorylation rates and enhances cooperativity.
Kennedy MA; Xu Z; Wu Y; Sohl CD
Biochem Biophys Res Commun; 2019 Feb; 509(4):898-902. PubMed ID: 30638931
[TBL] [Abstract][Full Text] [Related]
15. Vascular dysmorphogenesis caused by an activating mutation in the receptor tyrosine kinase TIE2.
Vikkula M; Boon LM; Carraway KL; Calvert JT; Diamonti AJ; Goumnerov B; Pasyk KA; Marchuk DA; Warman ML; Cantley LC; Mulliken JB; Olsen BR
Cell; 1996 Dec; 87(7):1181-90. PubMed ID: 8980225
[TBL] [Abstract][Full Text] [Related]
16. Hereditary cutaneomucosal venous malformations are caused by TIE2 mutations with widely variable hyper-phosphorylating effects.
Wouters V; Limaye N; Uebelhoer M; Irrthum A; Boon LM; Mulliken JB; Enjolras O; Baselga E; Berg J; Dompmartin A; Ivarsson SA; Kangesu L; Lacassie Y; Murphy J; Teebi AS; Penington A; Rieu P; Vikkula M
Eur J Hum Genet; 2010 Apr; 18(4):414-20. PubMed ID: 19888299
[TBL] [Abstract][Full Text] [Related]
17. A xenograft model for venous malformation.
Goines J; Li X; Cai Y; Mobberley-Schuman P; Metcalf M; Fishman SJ; Adams DM; Hammill AM; Boscolo E
Angiogenesis; 2018 Nov; 21(4):725-735. PubMed ID: 29786783
[TBL] [Abstract][Full Text] [Related]
18. Development of Molecular Therapies for Venous Malformations.
Kangas J; Nätynki M; Eklund L
Basic Clin Pharmacol Toxicol; 2018 Sep; 123 Suppl 5():6-19. PubMed ID: 29668117
[TBL] [Abstract][Full Text] [Related]
19. Somatic Activating PIK3CA Mutations Cause Venous Malformation.
Limaye N; Kangas J; Mendola A; Godfraind C; Schlögel MJ; Helaers R; Eklund L; Boon LM; Vikkula M
Am J Hum Genet; 2015 Dec; 97(6):914-21. PubMed ID: 26637981
[TBL] [Abstract][Full Text] [Related]
20. Ligand oligomerization state controls Tie2 receptor trafficking and angiopoietin-2-specific responses.
Pietilä R; Nätynki M; Tammela T; Kangas J; Pulkki KH; Limaye N; Vikkula M; Koh GY; Saharinen P; Alitalo K; Eklund L
J Cell Sci; 2012 May; 125(Pt 9):2212-23. PubMed ID: 22357955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
